Childhood Obesity
Pipeline by Development Stage
Metabolic Diseases is a $70.5B mature market dominated by diabetes and anticoagulation therapies with sustained blockbuster momentum.
Key Trends
- GLP-1 agonists (Ozempic, Mounjaro) driving explosive growth and market consolidation
- SGLT2 inhibitors expanding beyond diabetes into cardio-renal indications
- Significant patent cliff risk 2027-2029 for DPP-4 inhibitors (Januvia) and older insulins
Career Verdict
Excellent opportunity for specialists seeking stable, high-revenue exposure with strong hiring momentum in commercial and engineering roles.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 26% | Launch | Stable | 14.9yr |
| 2 | OZEMPIC (semaglutide) | Novo Nordisk | $9.2B | 13% | Peak | Growing | 12.3yr |
| 3 | JARDIANCE (empagliflozin) | Boehringer Ingelheim | $8.8B | 12% | Peak | Growing | 8.5yr |
| 4 | TRULICITY (dulaglutide) | Eli Lilly and Company | $7.4B | 10% | Peak | Stable | |
| 5 | FARXIGA (dapagliflozin) | AstraZeneca | $4.3B | 6% | Peak | Growing | 15.3yr |
Drug Class Breakdown
stable, mature franchise
rapid growth, expanding indications
growing, cardio-renal expansion
stable, generics pressure
declining, patent cliff 2027
Career Outlook
GrowingMetabolic diseases offers stable, high-value career trajectory with blockbuster product revenue supporting competitive compensation and long-term job security. Commercial and field-based roles dominate hiring, reflecting the shift toward patient access, digital health, and device integration in diabetes management. Patent cliff exposure in DPP-4 class (2027-2029) creates near-term volatility for Merck but limited impact on overall market given GLP-1 dominance.
Breaking In
Target device companies (Insulet, Abbott) or diagnostic firms for entry-level roles if traditional pharma hiring is limited; strong foundation in diabetes biology and HbA1c/CGM metrics will accelerate credibility.
For Experienced Professionals
Experienced professionals should prioritize GLP-1 franchise or SGLT2 indication expansion roles; avoid Merck DPP-4-focused assignments given 2027 patent cliff, unless willing to transition to next-generation pipeline.
In-Demand Skills
Best For
Hiring Landscape
Hiring activity is concentrated in commercial roles (166 positions) and engineering (126 positions), driven by device makers (Insulet: 270 jobs) and diagnostic companies (Abbott: 154 jobs) rather than traditional pharma. Sanofi leads pharma hiring with 42 metabolic-focused positions, but specialized roles in clinical operations remain constrained. Salary expectations range from $153K (Clinical Ops) to $274K (Manufacturing), with strong compensation for commercial and quality roles.
Top Hiring Companies
By Department
Strongest hiring momentum in device/delivery and commercial infrastructure; traditional pharma R&D roles remain limited despite blockbuster pipeline.
Competitive Landscape
13 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 30 trials with date data
Clinical Trials (30)
Total enrollment: 18,084 patients across 30 trials
IT-Supported Early Treatment Of Childhood Overweight
School Meals in Denmark
Family Intervention to Prevent Childhood Obesity
Generation Healthy Kids: A Cluster-randomized Trial of a Multi-component, Multi-setting Intervention
Family, Responsibility, Education, Support, and Health for Latino Caregivers (FRESH-LC)
Family Matters Intervention
A Cluster Randomized Trial of the H2GO! Program
A Mobile Phone Based Pilot Intervention to Prevent Obesity in Latino Preschool Children
Weight Stigma by Association in Parent-Child Dyads
Parenting Intervention for Pediatric Obesity
Efficacy Evaluation of a Mixed Compound of Antioxidants in Terms of Endothelium Damage/Function in Pediatric Subjects With Obesity.
Genetic Predisposition to Food Cue Reactivity in Children
Painted Playgrounds: Aim 2: Assessments
South Texas Early Prevention Studies PreK
Early Childhood Obesity Programming by Intrauterine Growth Restriction
Strong Futures: A Trial of Two Primary Care Based Interventions to Promote Optimal Health in Latino Infants and Toddlers
Painted Playgrounds Aim 1
Translational Investigation of Growth and Everyday Routines in Kids
Whole-exome Sequencing in Childhood Obesity
Simple Suppers Scale-up (S3)
Clinical Utility of SUDOSCAN in the Pediatric Population
Policy to Practice: Statewide Rollout of YMCA Childhood Obesity Standards
Effect of Dietary Fat Cooking Blend on Energy Expenditure in Children
Feeding, Fun, and Families Study
School Breakfast Policy Initiative Study
Mechanisms of Atherogenesis During Post-prandial Time in Childhood Obesity
Environmental Influences on Early Childhood Obesity
The Colorado LEAP Study: A Socioecological Approach to Obesity Prevention in Early Childhood
Metabolic Syndrome and Gen-polymorphs Influence on Weightloss Among Children in Treatment for Overweight
The Louisiana (LA) Health Project
Related Jobs in Metabolic Diseases
Principal Controls Engineer (Onsite)
Director, Project Leadership - New Product Introduction (Digital)
People Administrator (Nashville, TN)
Associate Mechanical Engineer (Onsite)
Sr Manager, Sales Operations (Hybrid - Acton, MA / San Diego, CA)
Financial Business Analyst
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.